Brand/Development name: Orplatna
Company(ies): GPC Biotech, Pharmion, Celgene
Principal Therapy Area: Cancer
£195 / $340 / €245
Satraplatin is an orally-active third-generation, class IV platinum derivative cancer drug. It binds to the DNA of cancer cells, making the cell incapable of dividing to form new cancer cells, and eventually the cell dies, halting tumour growth.
In August 2008, the EMEA was formally notified by Celgene of Pharmion's (now part of Celgene) decision to withdraw the application for a centralised marketing authorisation for satraplatin 10 and 50mg capsules. The drug was expected to be used, in combination with prednisone and prednisolone, for the treatment of patients with metastatic, hormone-refractory prostate cancer (HRPC) who have failed prior chemotherapy.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for email@example.com